HOME >> BIOLOGY >> NEWS
Gladstone researchers identify new drug target for Alzheimer's disease

San Francisco, Calif. (December 1, 2005)--Researchers at the Gladstone Institute of Neurological Disease have identified a potential new way to stop brain cell death related to Alzheimer's disease.

Working with cell cultures, the scientists investigated how amyloid beta proteins, which build up in the brain tissue of people with Alzheimer's disease, kill neurons. The cell cultures were established from brain tissue of laboratory rats. Study findings showed that amyloid beta could be prevented from causing neuronal cell death with a compound called resveratrol, which is also found as a natural ingredient in red wine.

"Our study suggests that resveratrol and related compounds may protect against neuronal loss associated with Alzheimer's disease," explains senior author Li Gan, PhD, a staff research investigator at the Gladstone Institute of Neurological Disease and an assistant professor of neurology at UC San Francisco. "This could certainly open up new avenues for drug development."

The research results are reported in the December 2 issue of the Journal of Biological Chemistry.

According to the research team, it was particularly interesting that the beneficial effect of resveratrol was not due to a direct impact on amyloid beta or on neurons but rather on other types of brain cells, called microglia.

Microglia are the immune cells of the brain. They can protect or hurt neurons, depending on which of their powerful defense or attack pathways are activated. The investigators found that amyloid beta triggers a pathway in microglia that makes them attack neurons with poisonous chemicals. A key mediator in this pathway is a protein called NF-kB, which resveratrol happens to block. Without resveratrol, amyloid beta activates NF-kB in microglia, turning them into powerful neuron killing machines. Researchers found that, in the presence of resveratrol or of other molecules that blocked NF-kB, microglia were well behaved, and
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
1-Dec-2005


Page: 1 2

Related biology news :

1. Gladstones Deepak Srivastava receives E. Mead Johnson Award for achievement in pediatrics
2. Gladstone scientists identify critical gene factor in heart development
3. Gladstone scientists prove neurons produce Alzheimers-linked apolipoprotein E
4. Gladstone Institutes receives funding for training grant from stem cell institute
5. Gladstone researchers hone in on differentiation of heart stem cells
6. Gladstone study links Alzheimers with toxic protein fragments
7. Gladstone Institutes assists with Exploratorium stem cell exhibit
8. CIRM awards $2.4 million training grant to the Gladstone Institutes
9. Gladstone investigators discover how resting T cells avoid HIV infection
10. Gladstone investigator Steve Finkbeiner wins prestigious Lieberman Award
11. Gladstone building honored with San Francisco Business Times award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... December 7, 2016 According to a new market research ... Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - ... grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, ... Continue Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... for Clinical Ops Executives 2017 in its continued commitment to the advancement of ... makers to discuss current issues related to clinical trial planning and management. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in ... Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award ... Department of Defense has announced the award of a new Advanced Regenerative Manufacturing ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers ... Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including ... issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and global ...
Breaking Biology Technology:
Cached News: